RGD Reference Report - Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3.

Authors: Zhang, YY  Li, JN  Xia, HH  Zhang, SL  Zhong, J  Wu, YY  Miao, SK  Zhou, LM 
Citation: Zhang YY, etal., Life Sci. 2013 Jul 10;92(24-26):1186-94. doi: 10.1016/j.lfs.2013.05.010. Epub 2013 May 20.
RGD ID: 9227415
Pubmed: PMID:23702425   (View Abstract at PubMed)
DOI: DOI:10.1016/j.lfs.2013.05.010   (Journal Full-text)

AIM: To investigate whether losartan has protective effects in mice with chronic viral myocarditis induced by coxsackievirus B3 (CVB3). MAIN METHODS: Thirty two male Balb/c mice were intraperitoneally injected with CVB3 (10xTCID50) to induce chronic viral myocarditis (CVM). Losartan at 12.5mg/kg (n=16) or normal saline (n=16) were orally administered daily for 28 days to these mice. Uninfected mice (n=6) were used as controls. On day 29, all mice underwent anesthesia and echocardiography prior to sacrifice. Serum IL-17, IL-4, IFN-gamma and TNF-alpha levels were measured by enzyme-linked immunosorbent assay, and cardiac tissues were histologically examined after hematoxylin & eosin staining. In addition, the effect of losartan on the virus titers in primary cultured neonatal rat cardiomyocytes infected with CVB3 was measured on Hep-2 cells at 72 h post infection. KEY FINDINGS: Mice infected with CBV3 had significantly increased mortality, heart/body weight ratios, necrosis and inflammatory scores and decreased cardiac ejection fractions, compared with the controls (all P<0.05). Losartan significantly decreased mortality from 40.0% to 12.5%, heart/body weight ratios from 7.08 +/- 2.17 to 4.15 +/- 0.99, and necrosis and inflammatory scores from 3.33 +/- 0.50 to 2.50 +/- 0.65 (all P<0.05), and increased ejection fractions from 55.80 +/- 9.25 to 72.31 +/- 12.15 (P<0.05). Losartan significantly enhanced IL-4, and decreased IFN-gamma, TNF-alpha and IL-17 (all P<0.05). In the in vitro experiment, losartan had no influence on virus titers. SIGNIFICANCE: Losartan protects mice against CVB3-induced CVM, most likely through upregulating Th2 responses, and down-regulating Th1 and Th17 responses.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
Viral Myocarditis treatmentISOIl17a (Mus musculus)9227415; 9227415 RGD 
Viral Myocarditis treatmentIDA 9227415 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Il17a  (interleukin 17A)

Genes (Mus musculus)
Il17a  (interleukin 17A)

Genes (Homo sapiens)
IL17A  (interleukin 17A)


Additional Information